Pregnant Patients With Opioid Use Disorder Still Miss Gold-Standard Treatment, Study Finds

Treatment gaps persist during a high-risk window

Medication treatment for opioid use disorder is widely regarded as the standard of care during pregnancy, yet a new U.S. study suggests that many patients still do not receive it. Researchers analyzing a large commercial insurance database found that only 40.2% of pregnant women diagnosed with opioid use disorder before or during pregnancy received medications for opioid use disorder, often called MOUD.

The finding matters because pregnancy is one of the clearest opportunities for the health system to identify opioid use disorder, stabilize care, and reduce risks for both parent and infant. The study, published online in

Drug and Alcohol Dependence

The analysis covered pregnancies from 2016 through 2020 among commercially insured women ages 15 to 54. Out of 909,241 pregnancies identified in the dataset, 2,926 women had an opioid use disorder diagnosis during pregnancy or postpartum. Even within that diagnosed group, medication treatment was far from routine.

Who was more likely to be diagnosed, and who was less likely to get treatment

The study examined factors associated both with diagnosis and with treatment uptake. Younger age and residence outside metropolitan statistical areas were positively associated with an opioid use disorder diagnosis. That suggests geography and age continue to shape where the burden of the disorder appears most clearly in the insured population studied.

When researchers looked at treatment receipt, they found a more complicated pattern. Pregnant women with chronic pain or another co-occurring substance use disorder were less likely to receive MOUD. By contrast, having two or more mental health disorders was positively associated with receiving medication treatment.

Those differences hint at how treatment access may depend not only on medical need, but also on how patients move through health systems. Some patients may be in closer contact with clinicians able to recognize and treat opioid use disorder. Others may encounter fragmented care, stigma, competing diagnoses, or uncertainty about managing multiple conditions during pregnancy.

The result is a treatment landscape that appears inconsistent at best. A patient can be diagnosed with a serious, treatable disorder and still not receive the therapy that clinical standards increasingly support.

Why the number is so consequential

Pregnancy often brings more frequent contact with doctors, clinics, and hospitals than many people have at any other time in adulthood. That makes the low treatment rate especially striking. If fewer than half of diagnosed patients receive medication during this period, the implication is not merely that care is imperfect. It is that a major clinical intervention is still failing to reach a large share of the people for whom it is intended.

The study does not attempt to explain every reason for the shortfall, but the finding lands in the middle of a broader national debate over how addiction care is delivered in obstetrics. In practice, patients may face insurance hurdles, provider shortages, lack of integrated prenatal and addiction services, and fear of judgment or legal consequences. The paper itself stays focused on claims data and associations, but the overall message is difficult to miss: diagnosis alone does not ensure treatment.

That gap has consequences beyond a single prescription. Medication treatment can be part of a broader care plan that includes prenatal monitoring, behavioral health support, and postpartum follow-up. Without it, the clinical burden shifts back onto patients already navigating a demanding and medically sensitive period.

What the study adds

Large national estimates are useful because they move the conversation beyond anecdote. This analysis did not rely on a single hospital system or one state program. Instead, it drew from a nationwide commercial insurance database, giving a broader view of treatment patterns among insured patients.

At the same time, the dataset also sets limits on what can be concluded. The study reflects people with commercial insurance, not the entire pregnant population. It measures diagnosed opioid use disorder rather than all underlying cases, which means undiagnosed patients are outside the count. And while it identifies patterns associated with treatment receipt, it does not establish why any one patient did or did not receive medication.

Still, the main finding is robust enough to shape policy and practice discussions. If medication is the gold standard and fewer than half of diagnosed pregnant patients receive it, then improving access is not a marginal adjustment. It is a central unfinished task.

Where intervention may matter most

The study’s subgroup findings may help focus that work. Patients with chronic pain and those with additional substance use disorder diagnoses appeared less likely to receive MOUD during pregnancy. Those are populations that may require more coordinated treatment models, not fewer. Their lower treatment rates suggest the presence of clinical complexity may be acting as a barrier rather than a trigger for more comprehensive care.

Meanwhile, the positive association between multiple mental health disorders and treatment receipt could indicate that contact with behavioral health services improves the odds of receiving evidence-based addiction care. If so, one lesson is that integration matters. Systems that connect obstetrics, psychiatry, and addiction treatment may be better positioned to deliver appropriate care than siloed models in which each condition is handled separately.

The authors said their findings underscore the need for targeted interventions. That likely means practical changes: screening that leads directly to treatment pathways, more clinicians prepared to prescribe and manage MOUD in pregnancy, and care models designed for patients with overlapping pain, mental health, and substance use needs.

The study does not claim to solve those problems. But it makes the treatment gap harder to ignore. In a population where the standard of care is well established and the health stakes are unusually high, fewer than half receiving medication is a number that demands a response.

This article is based on reporting by Medical Xpress. Read the original article.